| Abstract | Ebstein's anomaly (EA) is associated with poor outcome in symptomatic neonates. Management typically includes prostaglandins or surgical creation of a Blalock-Taussig shunt. Right ventricular afterload reduction may help by improving the forward flow across the pulmonary valve. We report the successful use of oral sildenafil, a pulmonary vasodilator, in a neonate with severe EA. |
| Authors | Sanjeev Aggarwal, Kavitha Chintala, Richard A Humes
(Affiliation: Division of Cardiology, The Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, Detroit, MI 48201, USA.)
|
| Journal | American journal of perinatology
(Am J Perinatol)
Vol. 25
Issue 2
Pg. 125-8
(Feb 2008)
ISSN: 0735-1631 United States |
| PMID | 18095215
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Piperazines
- Purines
- Sulfones
- Vasodilator Agents
- sildenafil
- Alprostadil
|
| Topics |
- Alprostadil
(therapeutic use)
- Ebstein Anomaly
(drug therapy, ultrasonography)
- Echocardiography
- Female
- Humans
- Infant, Newborn
- Piperazines
(therapeutic use)
- Purines
(therapeutic use)
- Sulfones
(therapeutic use)
- Vasodilator Agents
(therapeutic use)
|
